(Source: Sunesis Pharmaceuticals Inc) SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that two posters detailing preclinical data from its BTK and PDK1 inhibitor programs were presented on Sunday, November 8th at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, Massachusetts. The two poster presentations (Abstracts C198 and C186), titled 'SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation' and 'PDK1 inhibitors SNS-229 and SNS-510 cause pathway modulation, apoptosis and...
↧